Victory Capital Management Inc Gamida Cell Ltd. Transaction History

Victory Capital Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 06, 2023	BUY	$0.85 - $1.87 $9,307 - $20,476	10,950 New	10,950 $11,000
Q4 2022 Feb 09, 2023	SELL	$1.15 - $2.1 $10,574 - $19,309	-9,195 Reduced 8.03%	105,374 $135,000
Q3 2022 Nov 02, 2022	BUY	$1.53 - $3.39 $21,886 - $48,493	14,305 Added 14.27%	114,569 $182,000
Q4 2021 Feb 07, 2022	SELL	$2.2 - $4.46 $35,928 - $72,836	-16,331 Reduced 14.01%	100,264 $255,000
Q2 2021 Aug 03, 2021	SELL	$5.85 - $8.33 $33,660 - $47,930	-5,754 Reduced 4.7%	116,595 $747,000

Q1 2021 May 04, 2021	SELL	$7.8 - $12.43 $48,913 - $77,948	-6,271 Reduced 4.88%	122,349 $990,000
Q4 2020 Feb 01, 2021	SELL	$4.07 - $11.0 $37,073 - $100,199	-9,109 Reduced 6.61%	128,620 $1.08 Million
Q3 2020 Nov 09, 2020	SELL	$3.93 - $4.59 $228,164 - $266,481	-58,057 Reduced 29.65%	137,729 $572,000
Q2 2020 Aug 07, 2020	BUY	$2.79 - $6.5 $543,452 - $1.27 Million	194,786 Added 19478.6%	195,786 $895,000
Q4 2018 Feb 05, 2019	BUY	$8.44 - $15.41 $8,440 - $15,410	1,000 New	1,000 $10,000

11.4M

235K

70.5K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.